Unlock instant, AI-driven research and patent intelligence for your innovation.

Purpose of siRNA and membrane penetrating peptide for combined treatment of liver cancer

A technology for the treatment of liver cancer and membrane-penetrating peptides, applied in the fields of DNA/RNA fragments, gene therapy, recombinant DNA technology, etc., to achieve great application value, enhanced inhibitory effect, and improved transfection efficiency.

Active Publication Date: 2020-05-19
国科戎安生物科技(北京)有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is still room for improvement

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purpose of siRNA and membrane penetrating peptide for combined treatment of liver cancer
  • Purpose of siRNA and membrane penetrating peptide for combined treatment of liver cancer
  • Purpose of siRNA and membrane penetrating peptide for combined treatment of liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1 Cell Culture

[0028] 293T cells were placed in 5% CO using DMEM-F12 medium (supplemented with 10% fetal bovine serum and 1% penicillin and streptomycin) 2 Cultured in a cell culture incubator at 37°C, 1 day before transfection, trypsinized 293T cells and counted, 1*10 per well 5 Inoculated in 24-well culture plate, cultured in a cell incubator, so that the cell density was about 55% on the day of transfection.

Embodiment 2

[0029] Example 2 Cell Transfection and Measurement of Transfection Efficiency

[0030] The cells obtained in Example 1 were removed from the complete medium, washed twice with PBS, and 125ul of Opti-MEM medium (invitrogen) was used to dilute the siRNA (labeled FAM) of SEQ ID NO: 1 and the permeable peptide of SEQ ID NO: 3 ( (Shanghai Sangong Synthetic), mix the two evenly, let stand for 20min, then add to the cell culture plate, absorb the transfection medium after 4h, wash twice with PBS, add 500ul complete medium to each well and place in 5% CO 2 The transfected cells were obtained after culturing in a cell incubator at 37°C. Using LipofectamineTM RNAiMAX transfection reagent as a control, transfection was carried out under the same conditions, and the ratios of transfection reagent to siRNA were 1:1, 10:1, 20:1, and 25:1, respectively.

[0031] After 24 hours of transfection, detect the color development of FAM with an inverted fluorescence microscope and take pictures. Ca...

Embodiment 3

[0035] Example 3 Cytotoxicity detection

[0036] According to the method of Example 2, human H9 cells were only transfected with membrane-penetrating peptides, and the cells in each well 24 hours after transfection were digested with trypsin and sucked out respectively, and each well was divided into 1×10 4 Cells were inoculated into a 96-well culture plate and placed in a cell culture incubator with 5% CO2 at 37 degrees Celsius for 24 hours. The 96-well cell plate was removed from the old culture, washed twice with fresh DMEM medium, and 10 microliters of CCK-8 solution was added. Continue to incubate for 4 hours, use untransfected cells as control wells, detect the absorbance at a wavelength of 450nm with a microplate reader, and calculate the cell survival rate (OD of cells in the transfection group / OD of cells in the control group*100%), the results are as follows figure 2 As shown, after 24 hours of transfection, the permeable peptide has no obvious cytotoxicity to human...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a purpose of siRNA and membrane penetrating peptide for combined treatment of liver cancer. The siRNA has high restraining efficiency, the membrane penetrating peptide and thesiRNA can notably improve the transfection efficiency together, and after the membrane penetrating peptide and the siRNA are in combined use, the cancer restraining effect can be greatly strengthened, so that the combined use of the siRNA and the membrane penetrating peptide has good application prospects.

Description

technical field [0001] The present invention relates to the field of biology, in particular to the field related to cancer, and more specifically to the use of siRNA and membrane-penetrating peptide in the combined treatment of liver cancer. Background technique [0002] Hepatocellular carcinoma (HCC) is the most common pathological type of liver cancer. Worldwide, the death rate of liver cancer patients ranks second in the total death rate of all cancers. Especially in East Asia, Southeast Asia, Africa and southern Europe, the incidence and mortality of liver cancer are still on the rise. China accounts for about half of the global liver cancer incidence and death every year. Traditional surgical treatment is effective in improving the condition of some HCC patients, but a considerable number of patients are intolerant to treatment and have long-term recurrence and progression. Therefore, as the key to precise treatment in the future, HCC-related regulatory factors have ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/113A61K48/00A61K31/7105A61K47/42A61K47/18A61P35/00
CPCA61K31/7105A61K47/18A61K47/42A61P35/00C12N15/1135C12N2310/141
Inventor 王阳曹帅
Owner 国科戎安生物科技(北京)有限公司